On 31 October 2024, Daewoong Pharmaceutical announced that it has entered a joint sales agreement with Celltrion under which the two companies will jointly promote Celltrion’s CT-P41, biosimilar to Amgen’s Prolia® (denosumab), in Korea. CT-P41 is scheduled to be launched in the first half of 2025 in Korean hospitals and clinics.
This follows Celltrion’s presentation of 78 week results of its Phase 3 study of CT-P41 in April 2024, and the publication of those results in August 2024.
Celltrion filed an aBLA for CT-P41 in the US in December 2023 and, in May 2024, was sued by Amgen in the US District Court of New Jersey for alleged infringement of 29 patents regarding denosumab. That litigation is ongoing.